Xintela AB (FRA:1XT) FFO


FRA:1XT Xintela AB FRA:1XT
8 GF Score
Price €0.01
! 2 Warning Signs
View Full Analysis

What is Xintela AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:1XT
8GF Score
Xintela AB FRA:1XT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xintela AB Business Description

Other Exchanges XINT:Sweden
Address Medicon Village, Lund, SWE, 223 81
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score

Get the complete analysis for FRA:1XT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price